LifeVantage (LFVN) announced the results of a third-party cell study on the synergistic impact of Protandim Nrf2 Synergizer ...
Fintel reports that on January 14, 2025, Craig-Hallum initiated coverage of LifeVantage (NasdaqCM:LFVN) with a Buy ...
Craig-Hallum analyst Alex Fuhrman initiated coverage of LifeVantage (LFVN) with a Buy rating and $35 price target Discover ...
As previously reported, Craig-Hallum initiated coverage of LifeVantage (LFVN) with a Buy rating and $35 price target Interest in weight loss ...
LifeVantage's new MindBody GLP-1 System is riding the coattails of GLP-1 weight loss drugs. See why I rate LFVN stock as a ...
LifeVantage Corporation (Nasdaq: LFVN), a leader in cellular activation of optimal health processes, today announced the results of a groundbreaking third-party cell study on the synergistic impact of ...
As the U.S. stock market navigates a mixed landscape with the S&P 500 inching higher and tech stocks experiencing volatility, investors are keenly observing growth companies with substantial insider ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
LifeVantage shares soared Wednesday after the company said its financial outlook for 2025 is brighter than previously expected. The health and nutrition company's stock rose 30% to $21.40 in morning ...
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Sign up for our newsletter to get the latest on the ...
LifeVantage Corp. engages in the identification, research, development, formulation, and sale of nutraceutical dietary supplements and personal care products. Its products include Protandim ...
SALT LAKE CITY, Dec. 03, 2024 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the ...